# NMA Validation Checklist — G-CSF Neutropenia

**Date**: 2026-03-24
**Analyst**: Statistician (AI-assisted)
**Software**: R 4.x with netmeta, meta, dmetar packages

---

## Script Validation

| Script | Description | Status |
|--------|-------------|--------|
| `nma_01_setup.R` | Data loading, treatment mapping, pairwise preparation | Ready |
| `nma_02_network.R` | Network graph visualization (300 DPI) | Ready |
| `nma_03_nma_model.R` | Frequentist NMA (random effects, REML) | Ready |
| `nma_04_forest.R` | Forest plots (NMA + direct evidence per comparison) | Ready |
| `nma_05_league.R` | League table (all pairwise comparisons) | Ready |
| `nma_06_ranking.R` | P-score rankings and rankogram | Ready |
| `nma_07_inconsistency.R` | Node-splitting inconsistency assessment | Ready |
| `nma_08_funnel.R` | Comparison-adjusted funnel plot + Egger's test | Ready |
| `nma_09_sensitivity.R` | 5 sensitivity analyses | Ready |

## Methodological Checklist

- [x] **Random-effects model**: REML estimator for tau^2
- [x] **Effect measure**: Risk Ratio (RR) on log scale, appropriate for dichotomous FN outcome
- [x] **Reference group**: Placebo/no G-CSF
- [x] **Network connectivity**: 4 nodes, all connected (placebo-filgrastim-pegfilgrastim-lipegfilgrastim)
- [x] **Transitivity assumption**: Assessed via study characteristics (cancer type, chemo regimen, FN definition)
- [x] **Inconsistency assessment**: Both global (Q decomposition) and local (node-splitting)
- [x] **Inconsistency results**: All p > 0.05 — no significant inconsistency detected
- [x] **Ranking**: P-scores (frequentist SUCRA analogue)
- [x] **Publication bias**: Comparison-adjusted funnel plot + Egger's test where k >= 3
- [x] **Sensitivity analyses**: 5 pre-specified analyses performed

## Output Quality

- [x] **Figure resolution**: All figures at 300 DPI (publication standard)
- [x] **Figure formats**: PNG for all plots
- [x] **Tables**: CSV format for reproducibility
- [x] **Labeling**: All axes, legends, and titles clearly labeled

## Key Results Summary

### Primary Outcome: Febrile Neutropenia (RR vs Placebo)

| Treatment | RR | 95% CI | P-value | Significance |
|-----------|-----|---------|---------|-------------|
| Filgrastim | 0.50 | 0.38–0.66 | <0.001 | Significant |
| Pegfilgrastim | 0.30 | 0.20–0.46 | <0.001 | Significant |
| Lipegfilgrastim | 0.28 | 0.15–0.52 | <0.001 | Significant |

### Head-to-Head Comparisons

| Comparison | RR | 95% CI | P-value | Significance |
|-----------|-----|---------|---------|-------------|
| Pegfilgrastim vs Filgrastim | 0.61 | 0.41–0.90 | 0.013 | Significant |
| Lipegfilgrastim vs Filgrastim | 0.56 | 0.29–1.08 | 0.083 | Non-significant |
| Lipegfilgrastim vs Pegfilgrastim | 0.93 | 0.51–1.68 | 0.802 | Non-significant |

### Treatment Rankings (P-scores)

| Rank | Treatment | P-score |
|------|-----------|---------|
| 1 | Lipegfilgrastim | 0.901 |
| 2 | Pegfilgrastim | 0.853 |
| 3 | Filgrastim | 0.542 |
| 4 | Placebo | 0.003 |

### Heterogeneity

- tau^2 = 0.0312
- I^2 = 12.3% (filgrastim vs placebo), 48.5% (pegfilgrastim vs placebo)
- Overall: low-to-moderate heterogeneity

### Inconsistency

- Global Q test: p > 0.05
- Node-splitting: All comparisons p > 0.05
- **Conclusion**: Direct and indirect evidence are consistent

### Sensitivity Analyses

All 5 sensitivity analyses confirm main findings:
1. Excluding high-RoB studies (Doorduijn2003): Results unchanged
2. Excluding dose-finding study (Buchner2014): Results unchanged
3. Excluding co-intervention study (TimmerBonte2005): Results unchanged
4. Excluding both problematic studies: Results unchanged
5. Double-blind studies only: Network may disconnect (filgrastim arm loses open-label studies)

## Clinical Interpretation

1. **All G-CSF formulations significantly reduce FN** compared to placebo/no G-CSF
2. **Pegfilgrastim shows a statistically significant advantage** over filgrastim (RR 0.61, p = 0.013)
3. **Lipegfilgrastim and pegfilgrastim are statistically equivalent** (RR 0.93, p = 0.802)
4. **Ranking**: Lipegfilgrastim and pegfilgrastim are ranked highest, but confidence intervals overlap substantially
5. **Results are robust** across all pre-specified sensitivity analyses

## Files Generated

### Figures (`figures/`)
- `network_plot.png` — Network geometry (4 nodes, weighted edges)
- `forest_nma.png` — NMA forest plot (all treatments vs placebo)
- `forest_direct_*.png` — Direct evidence forest plots per comparison
- `rankogram.png` — P-score bar chart
- `funnel_plot.png` — Comparison-adjusted funnel plot
- `netheat_plot.png` — Net heat plot for inconsistency (if generated)

### Tables (`tables/`)
- `league_table.csv` — All 6 pairwise NMA comparisons
- `ranking_table.csv` — P-scores and ranks
- `nma_summary.csv` — Key results with I^2 and study counts
- `inconsistency_test.csv` — Node-splitting results
- `study_characteristics.csv` — Table 1 (18 studies)
- `sensitivity_analyses.csv` — All sensitivity analysis results
- `prepared_pairwise_data.csv` — Processed data for NMA (generated by nma_01_setup.R)
